Cy­tomX shares plum­met as Am­gen-part­nered can­cer drug yields jum­bled Phase 1 da­ta

Cy­tomX and Am­gen’s T cell en­gager showed mixed ef­fi­ca­cy sig­nals in an ear­ly tri­al in ad­vanced sol­id tu­mors, send­ing the biotech’s shares down 37% even …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.